AI-Based Platforms Are Shaping the IVF Industry

Rising lifestyle-related issues, combined with the hustle and bustle of everyday life, have had a substantial impact on health, particularly on young men and women’s fertility potential. Infertility is often regarded to be a feminine issue, but in recent years, more individuals have become aware it affects both males and females in equal numbers.
 
The global in-vitro fertilization (IVF) market is projected to reach $987 million by 2026 from $638 million in 2021, at a CAGR of 9.1 percent from 2021 to 2026. An increase in the median age of first-time mothers, diminishing fertility rates, rising male infertility, rising obesity rates, increased alcohol use, and more public awareness about infertility and treatment choices are some of the important factors driving this market’s growth.
 
As a relatively new discipline of medicine, fertility treatment benefits from a lack of historical baggage in terms of scientific approaches to treating couples. Technological developments and greater research in this discipline may bring up new potential for the IVF services industry over the next 8-10 years.
 
Every century seems to produce a world-changing scientific breakthrough: McCarthy’s artificial intelligence is transforming the world as we know it in the twenty-first century in a similar way.
 
“Nothing is lost, nothing is created, everything is altered,” said the famous chemist Antoine Lavoisier. “Everything AI touches undergoes a transformation. Could artificial intelligence for reproduction (repro-AI) have a similar impact on our industry?”
 

The Use of Technology to Manage the IVF Workflow
 

A good fertility clinic with established practices can use proven technology in IVF workflow management to properly define protocols and implement these workflows, resulting in higher success rates for couples. The important point is it’s the careful application of technology for processes and operational excellence, not innovation, that will make a difference and ensure seamless service delivery.
 

AI: The Silver Lining
 

Artificial intelligence (AI) infertility therapy is exploding at a breakneck pace, with a wide range of applications ranging from estimating reproductive potential to IVF treatment success rates. To interpret diverse clinical characteristics and make meaningful conclusions from them, deep data science and intelligence are necessary. Another area where solutions are being developed is high-resolution image processing technology to interpret and decipher embryo images to forecast the correct grading and quality of embryos for maximum pregnancy success.
 
Multiply has developed an AI-based platform specifically designed to enable simpler systems for fertility clinics, less hassle for doctors, and an effortless experience for patients by establishing a standard protocol for maintaining a safe, secure, and accurate database.
 
Quality control, embryo and oocyte Vitrification, and biopsy sample loading are just a few of the crucial but time-consuming and repetitive, recurrent procedures in the IVF lab that require extreme attention to detail. Employee productivity has been shown to be reduced over time by repetitive and monotonous jobs that demand the highest level of detail and precision—the feared embryologist “burn out.”
 
Automation is one of the most frequently mentioned advantages of AI. In a variety of economic areas, AI automation has already resulted in higher production rates and increased productivity. Automation in the ARTs tantalizes with the promise of eliminating the tediously routine, subjective, manual, and time-consuming tasks that dominate in the embryology lab, such as embryo grading, semen analysis, and quality assurance, while potentially contributing to increased safety and standardization.
 
Another advantage of AI automation is it promises to liberate the “bottleneck” of embryologists’ time from routine laboratory chores, allowing them to focus on more critical duties such as ICSI, embryo biopsy, and junior staff training. There is an increasing demand for experienced embryologists, but there is a scarcity; sadly, crucial mentorship takes time. AI-driven automation microfluidics and robots can help embryo culture systems utilize their raw resources more efficiently, such as culture media, chemicals, and plastics.
 
IVF clinics will not tolerate administrative or laboratory errors. Patient identification, a chain of custody, and cryo-storage inventory of tissues are frequently undertaken by “junior” embryologists to determine their readiness to be true “bench” embryologists. The embryology training model is based on low-level data entry. 
 
How many new embryologists had pricey educations, but left the industry before completing the one- or two-year term required to learn oocyte retrievals or deal with patient samples?
 
Through “chatbots” and natural language processing, AI-powered systems are also improving the customer experience by creating extremely specific responses to customer enquiries and grievances. By addressing regular inquiries regarding calendars, drug administration, embryo grading, or answering IVF cycle questions about alternatives, Repro-AI systems can relieve the load on lab and nursing staff. Telehealth paired with AI may one day allow clinicians to offer recommendations without the need for in-person office visits, bringing the “quasi-DIY” (do it yourself) IVF cycle to fruition, lowering costs, increasing convenience, and democratizing access for all.
 
Here comes Multiply, which is a central data center that houses crucial IVF patient information, as well as diagnostic listings, tests, and procedures regularly performed in IVF facilities. It gives doctors and other personnel quick and detailed documentation, guaranteeing that the clinic’s treatment regimens meet quality standards.
 

The Future Is Now with Artificial Intelligence
 

To handle complex problems, AI and machine learning (ML) is utilized to analyze data far more effectively than humans could ever collect, analyze, and/or understand.
 
While working in an ART, IVF, or the fertility clinic, there are several obstacles to overcome. The amount of data to be managed is one of the most difficult obstacles to overcome. Multiply makes it simple to enter and organize information on patients, treatments, tests, and equipment utilized, as well as manage appointments, timetables, and inventories. It gathers information from a variety of sources in an IVF clinic, including labs, operating rooms, consulting rooms, and registration desks, and arranges it in a user-friendly but secure manner. Without the need for a paper trail, every piece of information may be managed intelligently and smoothly.
 
Within the IVF business—universities, regulatory authorities, and professional groups—there is a vast pool of information and expertise. With a collaborative approach that allows both developers and adopters of repro-AI technologies to thrive, the industry will be able to provide the benefits of repro-AI to infertile patients rapidly and safely, despite substantial improvements in the area over the last 40 years.
 
The real-world repercussions of Einstein’s space-time continuum would not be realized for over a century until the first commercial GPS devices adjusted for the considerable warp in the space-time continuum caused by Earth’s mass. The advantages of repro-AI will be realized in a shorter period of time. However, the widespread adoption of repro-AI will be contingent on the development and widespread adoption of enabling technologies such as time-lapse microscopy, single-step embryo culture, integrated clinical and laboratory digital health records, and environmental system monitoring. Some of these technologies, such as “lab on a chip” (end-to-end IVF, ICSI, biopsy, and embryo freezing in a box) and “DIY” IVF cycles, are just beginning to be imagined.

---

Aniket Tapre is CEO of Multiply, a U.S.-based IVF-tech startup. To learn more on AI-based platforms in IVT industry visit https://multiply.is